PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
34833355-6	2021	The prophylactic administration of BB in the murine model of UC reduced histological damage, decreased the expression of IL-1beta (61.12%), IL-6 (94.70%), and TNF-alpha (68.88%), and increased the expression of INF-gamma (177.06%), IL-4 (541.36%), and IL-10 (531.97%).	boeravinone B	35-37	interleukin 6	Mus musculus	140-144	
17379004-0	2007	Limitation by p70 S6 kinase of platelet-derived growth factor-BB-induced interleukin 6 synthesis in osteoblast-like MC3T3-E1 cells.	boeravinone B	62-64	interleukin 6	Mus musculus	73-86	
34193671-13	2021	BB treatment considerably reduced the cytokines include tumor necrosis factor-alpha (TNF-alpha), interleukin-18 (IL-18), interleukin-1beta (IL-1beta), interleukin-6 (IL-6) and inflammatory parameters such as transforming growth factor beta 1 (TGF-beta1), prostaglandin E2 (PGE2), nuclear kappa B factor (NF-kappaB) and cycloxgenase-2 (COX-2) in DMBA/croton-induced skin cancer mice.	boeravinone B	0-2	interleukin 6	Mus musculus	151-164	
34193671-13	2021	BB treatment considerably reduced the cytokines include tumor necrosis factor-alpha (TNF-alpha), interleukin-18 (IL-18), interleukin-1beta (IL-1beta), interleukin-6 (IL-6) and inflammatory parameters such as transforming growth factor beta 1 (TGF-beta1), prostaglandin E2 (PGE2), nuclear kappa B factor (NF-kappaB) and cycloxgenase-2 (COX-2) in DMBA/croton-induced skin cancer mice.	boeravinone B	0-2	interleukin 6	Mus musculus	166-170